Noxopharm Ltd (ASX:NOX)’s new CEO and managing director Dr Gisela Mautner provides a corporate presentation to accompany the company’s newly released investor slide deck. The recording highlights the strategy for Noxopharm’s next stage of growth and the advancement of its key assets. Following a personal introduction, Dr Mautner discusses Noxopharm’s key priorities and pathway to the future, outlines Noxopharm’s current active clinical trial program and discusses Noxopharm’s two innovative preclinical technology platforms: Chroma™ and Sofra™.
Noxopharm details science-driven strategy in new investor presentation
